HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:B540-B542 (2004)
© 2004 The Gerontological Society of America

Anti-Aging Medicine: The History

The Three Avenues of Gerontology: From Basic Research to Clinical Gerontology and Anti-Aging Medicine. Another French Paradox

Leslie (Ladislas) Robert

Laboratoire d'Ophtalmologie, Hôtel Dieu, Université Paris-France.

Address correspondence to Leslie Robert, Laboratoire d'Ophtalmologie, Hôtel Dieu, Université Paris 5, 1 place du parvis Notre Dame, 75181 Paris cedex 04, France. E-mail: lrobert5{at}wanadoo.fr


    Abstract
 Top
 Abstract
 Anti-Aging Medicine
 What Can (and Should...
 References
 
This is a contribution to the debate raised by the position statement on aging ( 1) and comments ( 2) concerning the rapid increase of anti-aging medicine. After a short summary of the history of social attitude to aging and the emergence of experimental gerontology, the French situation is described, emphasizing the economic basis of this phenomenon: increasing insurance fees and tightly controlled honoraria push an increasing number of physicians to this new discipline. No lack of communication seems to be involved between basic gerontologists and physicians ( 2). Anti-aging medicine profits of the increasing population of seniors who want to remain healthy, look young and dislike to consult geriatricians. And also of the fact that no over-the-counter delivery of drugs is available in France. For these reasons there is no serious hope to stop it otherwise than by state legislation.


RESEARCH into the biology of aging and health care issues specific to older people are relatively recent enterprises. Older people have been known since antiquity but they were much more rare than today. Pline the Elder enumerated a number of exceptionally old people, not without some critical remarks (3). The Roman Senate was relatively "young," 40 years was already a respectable age. The number of seniors increased slowly over the centuries and they were not always well treated. The hospitals (hospices in French) that first treated old people are from the 17th century in France (Hospice de Tonnerre, Les Invalides in Paris, and others), though general hospitals had been around much earlier. Hôtel Dieu in Paris, for example, was founded in the 7th century (651 AD). Several historians-sociologists described the difficult years of older persons in France; the relationship between old people and the rest of society was far from ideal (4).

Ambroise Paré (1509–1590), the famous French surgeon, who invented the arterial ligature, subdivided human life into 4 periods: puerility, adolescence, youth, and virility, then old age. Old age was divided into 2 parts: from 35 to 49 years and 50 years and older, which was divided into 3 phases: 1) some manly virtues maintained; 2) imbecility of virtues; and 3) extreme imbecility, impatience, and reversion to a second childhood.

In the second half of the 19th century and early 20th century, some major clinical professors of the Viennese School (for instance Wagner-Jauregg, who initiated the malaria-heat shock for tertiary syphilis) began to write books on aging, perhaps motivated by their own ascendency in age. Much of the early approach to aging appears to have emphasized attempts at rejuvenation. The first largely publicized experiments of rejuvenation date to the end of the 19th century. Brown-Sequard, a French endocrinologist (1817–1894), self-injected aqueous testicular extracts with self-reported "miraculous" rejuvenating effect. As testosterone is not hydrosoluble, the pharmacological basis of this self-observation remains doubtful.

Biogerontology emerged in the first half of the 20th century when more reliable and scientific observations were reported. The still largely cited experiments of McCay with the low caloric diet increasing life expectancy of rats dates from the 1930s (5). The first reliable and reproducible experiments on tissue-aging produced by Fritz Verzar in Basel, Switzerland, date from the 1950s [see (6), for a review]. These observations were important for several reasons. They demonstrated that extracellular tissue components, such as collagen fibers, age independantly of other cellular components (postsynthetic, molecular aging). It was later discovered that the Maillard reaction—the result of direct (non enzymatically catalyzed) interaction between reducing sugars (glucose and others) and amino groups on proteins was responsible for some of the changes observed in the extracellular matrix [see (7) for review]. By the 1970s and 1980s, experimental gerontology was growing at a very rapid rate resulting in acceptance by the academic community and a solid score of important publications in areas ranging from molecular and cellular biology to demographic and epidemiological studies [e.g., see (8–14) for monographies on aging].

French clinical geriatrics has experienced a bumpy road. In France, a certain number of hospitals are entirely devoted to geriatrics, but geriatric homes are still insufficient to house all the older people unable to live alone. Geriatrics as a medical specialty is only partially recognized. Professorships do not exist in geriatrics, internists specialized in geriatrics are in competition with other internists for this nomination. Similar situations prevail in several other European Countries. In the standard medical curriculum only some faculties offer optional courses in gerontology and geriatrics. There are however post-graduate courses in gerontology. French gerontological society includes besides clinicians, members of the scientific community.

The inadequacy of the geriatric system was however cruelly exposed by the 2003 August heat wave producing an excess casualty of about 15,000 older French citizens. According to Profressor Françoise Forette, a specialist of age-related dementias, about 50% patients with an early Alzheimer's disease remain undiagnosed and account for a high proportion of frail and vulnerable older patients who deserve and require care from nurses with geriatric training. Such well trained nurses are in short supply in France. [The present proposition of the French Government to better subsidise care for the elderly is to "sacrifice" one day of yearly holiday with the income devoted to the above purpose.]

Another ageing-related field emerged in France known as "Aesthetic Medicine." Practitioners of this discipline earned a medical degree but do not follow the typical University curriculum leading to clinical professorship. Some are specialized in plastic surgery (similar to cosmetic surgery in the United States), others combine endocrinology, physiotherapy and similar medical disciplines. They are members of the French Society of Aesthetic Medicine which holds annual scientific meetings and hosts the Journal de Médecine Esthétique. The national meetings include sessions on basic sciences organized for instance on mechanisms of connective tissue aging as skin and similar topics related to the amelioration of the appearance of aging. Unlike the unfounded fountain of youth claims of the anti-aging industry, responsible physicians in France do have at their disposal a number of tools and strategies to make important differences in the quality of life of their old patients. This is particularly true for cardiovascular medicine where weight loss strategies, smoking cessation, and nutritional, exercise and pharmacological interventions certainly did play an important role in the decrease and postponement of fatal outcomes related to cardiovascular disease (15). Its low incidence in France contrasting with a relatively copious nutrition used to be designated as the "French paradox."

Courses in aesthetic medicine have recently received significant attention by the medical community. In 2002, there were 250 attendees (as compared to 30–40 in previous years), many of them formerly specialized in other disciplines (e.g., radiologists, anesthesiologists) at the Pharmacy Faculty of Paris course. A number of factors appear to be influencing the increased interest in this area including sky-rocketing medical insurance premiums, a relatively new phenomenon in France that is all too well known in the United States. Another force at work seems to be the growing number of older individuals with disposable income that are the main targets of anti-aging. In France the social observation was made among men and women age 50 and older, more youthful appearing person were more likely to keep their jobs, thus inducing for societal impetus to seek aesthetic medicine or anti-aging interventions. [IBM France used to put their staffmembers in preretreat from their 51st year (16)]. Speaking with some potential clients of anti-aging, I learned with some surprise that some older women find it psychologically unacceptable to consult a geriatrician.


    ANTI-AGING MEDICINE
 Top
 Abstract
 Anti-Aging Medicine
 What Can (and Should...
 References
 
Most recently the field of anti-aging medicine has emerged in France with the advent of the World Congress of Anti-Aging medicine organized by Dr. Legrand prominent in the French Society of Aesthetic Medicine together with the American Academy of Anti-Aging Medicine (A4M) and others from Asia and Europe. [The first anti-aging World Conference, subtitled Advanced Anti-Aging and Aesthetic Course for Global Patient Management, was held in Paris from February 22 to March 2, 2003 by the European Academy of Anti-Aging in partnership with A4M, the American Board of Anti-Aging Medicine, American Board of Anti-Aging Health Practitioners, Asia Pacific Academy of Anti-Aging Medicine, European Academy of Quality of Life and Longevity, European Centre for Aging Research and Education, German Society of Anti-Aging Medicine, International Academy of Anti-Aging Medicine, International Academy of Longevity Medicine, Japan Academy of Anti-Aging Medicine, Japan Anti-Aging Medical Association, National Academy of Sports Medicine, Collège Médical Français de Gérontologie, Société Belge de Médecine Anti-Âge, Union Internationale de Médecine Esthétique, World Anti-Aging Academy of Medicine, and World Anti-Aging Medical Association.] In 2002, 1600 physicians registered for the conference. For the 2004 conference (March 19–21), the Congress claimed they had already 2600 registrants by mid-2003.

One possible reason for the increasing interest in anti-aging medicine is the real financial pinch many professionals in the health care industry are feeling given the keen competition for faculty hospital appointments, increasing malpractice insurance fees, and increasingly limited reimbursement by social security with limitation of the medical honorarium. Thus they are exploring alternatives for securing income.

The above reasons insure the success of the A4M and World Congress meetings. Some basic scientists are invited to lecture, as I did myself last February (on basic mechanisms of aging) This gave me the opportunity to listen to some lectures by other faculty members. I recall the lecture of a highly regarded pharmacology professor who presented a lecture on age-related dementias. Every projection enumerating the symptoms of a given disease was followed by a projection enumerating the drugs, vitamins, and other so-called remedies that can be prescribed to such patients with no mention of their potential efficacy. Such lectures were very popular because they suggested ready-made recipes for "anti-aging" consultations. We shall see in the next few years where this new trend will lead. One major difference between France and the United States is that "anti-aging" neutriceuticals (DHEA, melatonin) can be obtained in France only by prescription whereas in the United States they are on free sale. In France, only vitamins are available over the counter. Thus, France is relatively lucky to still have some control over the situation.


    WHAT CAN (AND SHOULD BE) DONE
 Top
 Abstract
 Anti-Aging Medicine
 What Can (and Should...
 References
 
The only hope for the short term may come from the "patients" themselves if they recognize the uncertainties of some "anti-aging" therapies. The wide spread French character of being in constant revolt against anything might be a positive factor in this respect. I do believe however, as claimed also by some American colleagues (1,2) that the weight of arguments of basic scientists against "anti-aging" medicine has to be reoriented in favor of a more serious preparation for the resurgence of this pushing of the envelope, of claims that appear outlandish and impossible. In some cases we have to consider the possibility that such pushing could eventually transpire in gains with significant scientific merit. We should remember that the placebo effect can reach (and be over) 30% as shown by double-blind clinical trials against placebo, even of cardiovascular drugs. This figure could be even higher in the hands of some skilled "anti-aging" practitioners. Of course, a very cautious and responsible eye must be kept out for possible adverse side effects of drugs prescribed by anti-aging practitioners. The anti-aging industry has to learn that its eventual success will largely and solely depend upon the scientifically rigourous efforts of the gerontology community.


    Footnotes
 
Decision Editor: James R. Smith, PhD

Received October 9, 2003


    References
 Top
 Abstract
 Anti-Aging Medicine
 What Can (and Should...
 References
 

  1. Olshansky SJ, Hayflick L, Carnes BA. No truth to the fountain of youth. Sci Am. 2002:92.
  2. Juengst ET, Binstock RH, Mehlman MJ, Post SG. Anti-aging research and the need for public dialogue. Science. 2003;299:1323.[Abstract/Free Full Text]
  3. Pline the Elder. In: Histoire Naturelle de Pline. Vol. III. Traduction bilingue. Paris: Veuve DeSaint; 1771:173–101.
  4. Bois JP. Les Vieux (de Montaigne aux Première Retraites). Paris: Fayard; 1989.
  5. McCay CM, Crowell MF. Prolonging the life-span. Sci Monthly. 1934;39:405-414.
  6. Verzar F. Aging of the collagen fiber. In: Hall DA, ed. International Review of Connective Tissue Research. Vol II. New York: Academic Press; 1934:243–300.
  7. Baynes JW, Monnier VM, eds. The Maillard Reaction in Aging, Diabetes and Nutrition. New York: Alan R Liss; 1989.
  8. Hayflick L. How and Why We Age. New York: Ballantine Books; 1994.
  9. Macieira-Coelho A, ed. Molecular Basis of Aging. Boca Raton: CRC Press; 1995.
  10. Macieira-Coelho A. Biology of Aging. New York: Springer Verlag; 2003.
  11. Finch CE. Longevity, Senescence and the Genome. Chicago: University of Chicago Press; 1990.
  12. Robine JM, Vaupel JW, Jeune B, Allard M, eds. Longevity: To the Limits and Beyond. Berlin: Springer; 1997.
  13. Robert L. Le Vieillissement. Paris: Belin-CNRS; 1994.
  14. Robert L, Murata K, Nagai Y, eds. Degenerative Diseases of Connective Tissue and Aging. Kodansha Ltd.; 1985.
  15. Tunstall-Pedoe H, ed. MONICA Monograph and Multimedia Sourcebook. Geneve: WHO Editions; 2003.
  16. Forette F. La Révolution de la Longévité. Paris: Grasset; 1997.



This article has been cited by other articles:


Home page
GerontologistHome page
G. E. Alkema and D. E. Alley
Gerontology's Future: An Integrative Model for Disciplinary Advancement.
Gerontologist, October 1, 2006; 46(5): 574 - 582.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation


HOME ARCHIVE SEARCH TABLE OF CONTENTS